Related Experiment Video

Updated: Jan 10, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL

Rachel M Koldej1,2, Allison Barraclough3,4,5, Huw Morgan1,2

  • 1ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Blood Neoplasia
|November 24, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K

Related Experiment Videos

Last Updated: Jan 10, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K

Related Concept Videos

Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

8.4K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K

Articles linked to this work by shared authors, journal, and citation graph.

Compartment-Specific Recurrence in Medullary Thyroid Cancer.

JAMA otolaryngology-- head & neck surgery·2026

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

British journal of haematology·2026

Dynamic imaging markers of incident microhemorrhages and superficial siderosis in the A4 study: A longitudinal person-interval analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Haematologica·2026

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

European journal of haematology·2026

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology.

Nature methods·2026

Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib.

Blood neoplasia·2026

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.

Blood neoplasia·2026

Erratum: Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.

Blood neoplasia·2026

Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models.

Blood neoplasia·2026

Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.

Blood neoplasia·2026

Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression, and blocks myeloid differentiation.

Blood neoplasia·2026

Reversing Dysfunction of CCR9+ Regulatory T Cells by Targeting the IL-21/IL-17 Axis Improves Type 1 Diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026

The Patient With Multiple Alloantibodies: A Systematic Strategy for Antibody Identification and Transfusion Management.

Case reports in immunology·2026

Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us